Popular Articles

Blood Test Shows Statistically Significant Association With Alzheimer's Disease (AD), May Predict Conversion Of Mild Cognitive Impairment To AD
Dr. Zsuzsanna Nagy of the University of Birmingham presented data from a clinical study, funded by Cytox Limited, demonstrating that a simple blood-based biomarker discriminated between patients with Alzheimer"s disease (AD) and control subjects. The findings were statistically highly significant, and the test discriminated between the two groups with 80% sensitivity and 80% specificity. The results also showed that 40% of the mild cognitive impairment (MCI) patients tested had the same test results as AD patients. Follow up study of MCI patients enrolled in an earlier study found that the test allowed early identification of those MCI patients who later developed dementia. The results were presented at the 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009), held in Vienna, Austria.
diet pills
The Royal Society For Public Health Announces It Will Be Delivering Training Sessions
The Royal Society for Public Health (RSPH) announces it will be delivering training sessions for the RSPH Level 1 Health Awareness and the RSPH Level 2 Understanding Health Improvement awards.
News of the day
Radionuclide Contamination At DOE Sites Addressed By New Research
Five years from now, Lab scientists will be able to better determine how, when and why plutonium moves in soil and groundwater.
Medical Devices

Study Rewrites Textbook On Key Genetic Phenomenon

Because females carry two copies of the X chromosome to males" one X and one Y, they harbor a potentially toxic double dose of the over 1000 genes that reside on the X chromosome. To compensate for this imbalance, mammals such as mice and humans shut down one entire X-chromosome through a phenomenon known as X-inactivation. For almost two decades, researchers have believed that one particular gene, called Xist, provides the molecular trigger of X-inactivation. Now, a new UNC study appearing online July 1 in the journal Nature disputes the current dogma by showing that this process can occur even in the absence of this gene. "Our study contradicts what is written in the textbooks," said senior study author Terry Magnuson, Ph.D., Sarah Graham Kenan Professor and chair of genetics, director of the Carolina Center for Genome Sciences and a member of the UNC Lineberger Comprehensive Cancer Center. "Everybody thought that Xist triggers X-inactivation, but now we have to rethink how this important process starts." Previous studies showed that the Xist gene was active or "turned on" early in the course of X-inactivation and that disruptions in the gene resulted in irregular X-inactivation, eventually leading to the accepted assumption that Xist was the trigger. But it wasn"t clear in the literature if this genetic phenomenon would initiate if Xist isn"t present, said lead study author Sundeep Kalantry, Ph.D., postdoctoral fellow in the UNC department of genetics. Kalantry used three different molecular techniques to look at X-inactivation in the embryos of mice that were genetically engineered to contain a defective Xist gene on their future inactive X-chromosome. He discovered that the genes on this X-chromosome could be silenced regardless of whether they produced Xist. But while Xist was not absolutely required to start X-inactivation, without it genes along the X-chromosome eventually became active again. Thus, Xist appears to stabilize silencing of the X-chromosome over the long term. Unlike most genes, the Xist gene doesn"t code for a protein. Rather, it acts at the level of RNA - a copy of the DNA genetic sequence - which serves to recruit protein complexes through a process known as epigenetics. These proteins then form a molecular scaffold along the inactive-X chromosome that can stably silence the genes contained within it. The UNC researchers are now actively investigating how this chromosomal remodeling begins in the first place. "If we can figure out the mechanism that triggers X-inactivation, we can potentially apply this knowledge to diseases that have an epigenetic component," Kalantry said. "So it can have implications not only in fundamentally understanding X-inactivation but also to gain insight into the increasing array of illnesses where the epigenetic machinery has gone awry such as in prostate and breast cancers." Along with Magnuson and Kalantry, study co-authors are Sonya Purushothaman, undergraduate student; Randall Bryant Bowen, research technician; and Joshua Starmer; Ph.D., postdoctoral fellow. The research was supported in part by the National Institutes of Health and by an American Cancer Society Postdoctoral Fellowship. University of North Carolina


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):